Evidence map›Paper›PMID 26183166›Full record

ArticleMedical decision making : an international journal of the Society for Medical Decision Making2015

My Lived Experiences Are More Important Than Your Probabilities: The Role of Individualized Risk Estimates for Decision Making about Participation in the Study of Tamoxifen and Raloxifene (STAR).

Christine Holmberg, Erika A Waters, Katie Whitehouse, Mary Daly, Worta McCaskill-Stevens

Abstract read
In one paragraph

Article in Medical decision making : an international journal of the Society for Medical Decision Making, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Patient and Physician Perspectives on Using Risk Prediction to Support Breast Cancer Surveillance Decision Making.Medical decision making : an international journal of the Society for Medical Decision Making · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Translating Cancer Risk Prediction Models into Personalized Cancer Risk Assessment Tools: Stumbling Blocks and Strategies for Success.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. PARTICIPATORY BULLSEYE TOOLKIT INTERVIEW: IDENTIFYING PHYSICIANS' RELATIVE PRIORITIZATION OF DECISION FACTORS WHEN ORDERING RADIOLOGIC IMAGING IN A HOSPITAL SETTING.Proceedings of the International Symposium of Human Factors and Ergonomics in Healthcare. International Symposium of Human Factors and Ergonomics in Healthcare · 2018
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Christine HolmbergBerlin School of Public Health, Charité - Universitätsmedizin Berlin, Berlin, Germany (CH, KW)
Erika A WatersDepartment of Surgery, Washington University School of Medicine, St. Louis, MO, USA (EAW)
Katie WhitehouseBerlin School of Public Health, Charité - Universitätsmedizin Berlin, Berlin, Germany (CH, KW)
Mary DalyFox Chase Cancer Center, Philadelphia, PA, USA (MD)
Worta McCaskill-StevensNational Cancer Institute, Rockville, MD, USA (WM).

Funding

NRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5M
NCI NIH HHS UG1 CA189867NIMHD NIH HHS L60 MD006280PHS HHS UG1-189867
6 · The paper itself

Abstract

backgroundDecision-making experts emphasize that understanding and using probabilistic information are important for making informed decisions about medical treatments involving complex risk-benefit tradeoffs. Yet empirical research demonstrates that individuals may not use probabilities when making decisions.

objectivesTo explore decision making and the use of probabilities for decision making from the perspective of women who were risk-eligible to enroll in the Study of Tamoxifen and Raloxifene (STAR).

methodsWe conducted narrative interviews with 20 women who agreed to participate in STAR and 20 women who declined. The project was based on a narrative approach. Analysis included the development of summaries of each narrative, and thematic analysis with developing a coding scheme inductively to code all transcripts to identify emerging themes.

resultsInterviewees explained and embedded their STAR decisions within experiences encountered throughout their lives. Such lived experiences included but were not limited to breast cancer family history, a personal history of breast biopsies, and experiences or assumptions about taking tamoxifen or medicines more generally.

conclusionsWomen's explanations of their decisions about participating in a breast cancer chemoprevention trial were more complex than decision strategies that rely solely on a quantitative risk-benefit analysis of probabilities derived from populations In addition to precise risk information, clinicians and risk communicators should recognize the importance and legitimacy of lived experience in individual decision making.

Indexed as

Decision MakingHealth Knowledge, Attitudes, PracticeAdultAgedAntineoplastic Agents, HormonalBreast NeoplasmsChemopreventionEstrogen AntagonistsFemaleHumansInterviews as TopicMiddle AgedNational Cancer Institute (U.S.)ProbabilityRaloxifene HydrochlorideRisk AssessmentAntineoplastic Agents, HormonalEstrogen AntagonistsRaloxifene HydrochlorideTamoxifenbreast cancer riskchemopreventiondecision makingindividualized risk informationlived experiencesnarrative interviews

Identifiers

PMID26183166
PMCPMC4592416

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.